© 2021 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
December 14th 2015
Daniel R. Vlock, MD, founder and CEO, Alopexx Pharmaceuticals, discusses a phase I/II study of an antiâ€“CD20 interleukin-2 immunocytokine in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
End of data